Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: 2 mg/kg CR8020
BIOLOGICAL: 5 mg/kg CR8020
BIOLOGICAL: 15 mg/kg CR8020
BIOLOGICAL: 30 mg/kg CR8020
BIOLOGICAL: 50 mg/kg CR8020
BIOLOGICAL: Placebo

Sponsor

Crucell Holland BV

Collaborators

[object Object]